Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus CAPOX versus placebo plus CAPOX in first-line CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
NL-OMON52492Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Zolbetuximab + CAPOX with Placebo + CAPOX (2 arms). Primary endpoint: Progression-free survival. Started Oct 2020; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON52492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52492.